For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

As of close of business last night, KalVista Pharmaceuticals Inc’s stock clocked out at $15.61, down -2.19% from its previous closing price of $15.96. In other words, the price has decreased by -$2.19 from its previous closing price. On the day, 1.09 million shares were traded. KALV stock price reached its highest trading level at $16.14 during the session, while it also had its lowest trading level at $15.36.

Ratios:

To gain a deeper understanding of KALV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.16.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.

On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30. On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 08 ’25 when Palleiko Benjamin L sold 7,294 shares for $15.84 per share. The transaction valued at 115,537 led to the insider holds 395,189 shares of the business.

Sweeny Nicole sold 1,480 shares of KALV for $19,862 on Aug 25 ’25. The Chief Commercial Officer now owns 32,291 shares after completing the transaction at $13.42 per share. On Aug 25 ’25, another insider, Yea Christopher, who serves as the CHIEF DEVELOPMENT OFFICER of the company, sold 1,954 shares for $13.42 each. As a result, the insider received 26,223 and left with 132,052 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 785804288 and an Enterprise Value of 671349888.

Stock Price History:

The Beta on a monthly basis for KALV is -0.14, which has changed by 0.45615673 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $16.33, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 12.15%, while the 200-Day Moving Average is calculated to be 34.53%.

Shares Statistics:

It appears that KALV traded 1.25M shares on average per day over the past three months and 951750 shares per day over the past ten days. A total of 49.76M shares are outstanding, with a floating share count of 37.46M. Insiders hold about 25.02% of the company’s shares, while institutions hold 87.55% stake in the company. Shares short for KALV as of 1755216000 were 10036717 with a Short Ratio of 8.00, compared to 1752537600 on 9251558. Therefore, it implies a Short% of Shares Outstanding of 10036717 and a Short% of Float of 22.45.

Earnings Estimates

The firm’s stock currently is rated by 7.0 analysts. The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.75 and low estimates of -$1.0.

Analysts are recommending an EPS of between -$1.95 and -$3.71 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$1.8, with 7.0 analysts recommending between $0.4 and -$2.78.